Professor Dr. Peter Gruss, President of the Max Planck Society, nominated to Actelion's Board
(Thomson Reuters ONE) -
Actelion Pharmaceuticals Ltd /
Professor Dr. Peter Gruss, President of the Max Planck Society, nominated to
Actelion's Board
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
New Board nominee with outstanding scientific and managerial background to
immediately provide advisory services
ALLSCHWIL/BASEL, SWITZERLAND - 30 November 2011 - Actelion (SIX: ATLN) today
announced the nomination of Professor Dr. Peter Gruss for election to the
Company's Board of Directors (BoD) at the 2012 Annual General Meeting (AGM) of
shareholders, to be held on 4 May 2012.
Prof. Gruss, a molecular biologist by training and head of the German research
organization Max Planck Society, will, as of 1 December 2011, start to play an
active role as a scientific adviser to the Actelion BoD. If elected, he will
then join as a full Board member at the AGM 2012.
Jean-Pierre Garnier, Chairman of Actelion's Board of Directors, commented: "We
are extremely fortunate that Prof. Gruss is prepared to join Actelion's Board.
Peter has had an exemplary career, both as a scientist and as a research
executive, leading the Max Planck Society since 2002. I expect that his
involvement and addition to our Board will further strengthen and guide our
ongoing efforts to turn scientific discoveries into value-creating medicines for
all stakeholders."
###
About Professor Gruss
Peter Gruss has been President of the Max Planck Society since 2002. He became a
Scientific Member of the Max Planck Society in 1986, when he was appointed as
Director at the Max Planck Institute for Biophysical Chemistry in Göttingen. He
earned his PhD in biology at the University of Heidelberg and is honorary
professor at the University of Göttingen.
Peter Gruss began his scientific career as a research assistant at the Institute
for Virus Research in Heidelberg in 1977. From there, he moved on to the
National Institutes of Health in Bethesda, Maryland, initially as a post-doc
associate, and later as an expert consultant. In 1982, he was appointed as
Professor at the Institute for Microbiology at the University of Heidelberg.
Over the years, he has received several honors, including the Leibniz Prize, the
Louis-Jeantet Prize for Medicine, the German Prize for Technology and Innovation
by the President of the Federal Republic of Germany, the Lower Saxony State
Prize, as well as the German Federal Cross of Merit.
As President of the Max Planck Society, Peter Gruss holds numerous offices and
functions. Among others, he is a member of the Senates of the Alliance of
Scientific Organizations in Germany, the German Research Foundation (DFG), the
German National Academy of Sciences Leopoldina, as well as of acatech, the
German Academy of Science and Engineering. In addition, he is member of the
Supervisory Boards of Siemens AG and Munich RE, as well as of the Advisory Board
of Deloitte. He was appointed as a member of the "Innovation Dialogue" of the
Federal Chancellery by Angela Merkel.
About the Max Planck Society
The Max Planck Society is Germany's most successful research organization. Since
its establishment in 1948, no fewer than 17 Nobel laureates have emerged from
the ranks of its scientists, putting it on a par with the best and most
prestigious research institutions worldwide. The more than 13,000 publications
each year in internationally renowned scientific journals are proof of the
outstanding research work conducted at Max Planck Institutes -many of those
articles are among the most-cited publications in their relevant fields.
Actelion Ltd.
Actelion Ltd is a biopharmaceutical company with its corporate headquarters in
Allschwil/Basel, Switzerland. Actelion's first drug Tracleer®, an orally
available dual endothelin receptor antagonist, has been approved as a therapy
for pulmonary arterial hypertension. Actelion markets Tracleer® through its own
subsidiaries in key markets worldwide, including the United States (based in
South San Francisco), the European Union, Japan, Canada, Australia and
Switzerland. Actelion, founded in late 1997, is a leading player in innovative
science related to the endothelium - the single layer of cells separating every
blood vessel from the blood stream. Actelion's over 2,500 employees focus on
the discovery, development and marketing of innovative drugs for significant
unmet medical needs. Actelion shares are traded on the SIX Swiss Exchange
(ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market
Index SMI®).
For further information please contact:
Roland Haefeli
Senior Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36
www.actelion.com
--- End of Message ---
Actelion Pharmaceuticals Ltd
Gewerbestrasse 16 Allschwil Switzerland
ISIN: CH0010532478;
Press Release PDF:
http://hugin.info/131801/R/1567713/487153.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE
[HUG#1567713]
Unternehmensinformation / Kurzprofil:
Datum: 30.11.2011 - 17:35 Uhr
Sprache: Deutsch
News-ID 92806
Anzahl Zeichen: 6389
contact information:
Town:
Allschwil
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 242 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Professor Dr. Peter Gruss, President of the Max Planck Society, nominated to Actelion's Board"
steht unter der journalistisch-redaktionellen Verantwortung von
Actelion Pharmaceuticals Ltd (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
